PolyPid Ltd.

NASDAQ:PYPD

Biotechnology

Healthcare
$6.56 +8.23%

+$0.39 today

Market cap
$133.25M
Beta
1.43
P/E (TTM)
-2.7
EPS (TTM)
-$1.53
52W Low $3.06High $5.21

Volume 0.30M

Average 0.09M

PYPD Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

PolyPid Ltd.NASDAQ: PYPD

Other Non-Cash Items · Q4 FY2025 · quarter ended Dec 2025

Other non-cash items of $8.47M in Q4 FY2025

Q4 FY2025 other non-cash items was $8.47M. Trailing-twelve-month other non-cash items was $34.17M. Over 3 fiscal years it compounded at +95.2% a year.

Context

  • Other non-cash items increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other non-cash items holds near $8.47M or moves back toward the trailing-twelve-month quarterly average of $8.54M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$8.47M+13.7% QoQ
Last fiscal yearDec 2025
$34.17M+870.4% YoY
LTMDec 2025
$34.17M— YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+870.4%——
3-year CAGR+95.2%——
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
34.17M USD
Year-over-year change
+870.4%
4-year CAGR
+63.8%

Other Non-Cash Items vs competitors

How PYPD compares with its peers on the latest reported figures

  • PYPD's LTM Dec 2025 other non-cash items of $34.17M is the 2nd largest of the 7 companies compared; the peer median is $91.64K.
  • Over three fiscal years its annual growth of +95.2% compares with a peer median of +299.3%.
PYPD Competitors Peer median
Other Non-Cash Items for PYPD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PDSBPDS Biotechnology CorporationLTM Mar 2026$20.21B +1471660.5%+482.8%—
PYPDPolyPid Ltd.LTM Dec 2025$34.17M —+95.2%—
CELUCelularity Inc.LTM Dec 2025$27.2M +141.4%—102.4%
VERUVeru Inc.LTM Mar 2026$11.33M +573.0%+115.7%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$1.23M ——3.5%
ANVSAnnovis Bio, Inc.LTM Mar 2026$148K -96.6%——
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$35.29K -98.1%——
Peer median (excluding PYPD) $91.64K+141.4%+299.3%53.0%

Competitors are the stored peer set for PYPD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(42.6M)(39.56M)(23.87M)(29.02M)(34.17M)
Depreciation & Amortization1.12M1.72M1.82M1.62M0
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital4.35M(1.08M)(110K)1.92M0
Accounts Receivables123K0000
Inventory00000
Accounts Payables2.22M(3.1M)(369K)1.64M0
Other Working Capital2M2.02M259K279K0
Other Non-Cash Items4.75M4.6M4.92M3.52M34.17M
Operating Cash Flow(32.39M)(34.32M)(17.24M)(21.96M)0
Capital Expenditures(2.99M)(1.77M)(196K)(76K)0
Acquisitions (Net)00000
Purchases of Investments00(18.6M)(21.35M)0
Sales of Investments39.89M18.34M22.6M21.1M0
Other Investing Activities00000
Investing Cash Flow36.9M16.58M3.8M(330K)0
Debt Repayment011.31M(2.62M)(3.32M)0
Common Stock Issued1.03M5.12M12.72M35.86M0
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00(125K)(125K)0
Financing Cash Flow1.03M16.43M9.98M32.42M0
Effect of Forex Changes(41K)161K2K77K(9.21M)
Net Change in Cash5.51M(1.15M)(3.45M)10.2M(9.21M)
Free Cash Flow(35.38M)(36.08M)(17.43M)(22.04M)0

PolyPid Ltd.

NASDAQ:PYPD

Intrinsic Alpha fair value

Locked

Current Price

$6.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.